 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12345678910111213...235236» |
- Avastin (bevacizumab) / Roche, Kaitanni (cadonilimab) / Akesobio
Preliminary safety and efficacy of upfront FOLFOXIRI and bevacizumab with cadonilimab in patients with proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer: A multicenter phase II study (SYLT-026). (Level 1, West Hall; Poster Bd #: H10) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_857;
P2
Clinical Trial Registration Number: NCT05839470. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Avastin (bevacizumab) / Roche, botensilimab (AGEN1181) / Agenus, balstilimab (AGEN2034) / Agenus
A phase 1 trial of folinic acid, fluorouracil, oxaliplatin, bevacizumab, botensilimab, balstilimab (FOLFOX-3B) in microsatellite stable metastatic colorectal cancer. (Level 1, West Hall; Poster Bd #: G18) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_841;
P1/2
Clinical Trial Registration Number: NCT05627635. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
A multicenter, prospective phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to anti-EGFR agents (HGCSG1801): Updated analyses. (Level 1, West Hall; Poster Bd #: F8) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_830;
Clinical Trial Registration Number: jRCTs011190006. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Fruzaqla (fruquintinib) / Takeda
Fruquintinib combined with FOLFIRI/mFOLFOX6 as second-line treatment in patients with RAS-mutant metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study. (Level 1, West Hall; Poster Bd #: F12) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_813;
P2
Clinical Trial Registration Number: NCT05634590. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Avastin (bevacizumab) / Roche
Total neoadjuvant therapy with FOLFOX plus bevacizumab and short-course radiotherapy for Ras mutant, high-risk, locally advanced rectal cancer: The TRAINER trial. (Level 1, West Hall; Poster Bd #: E19) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_803;
P
Clinical Trial Registration Number: NCT04923620. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- ozekibart (INBRX-109) / Inhibrx Biosci
Tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) + FOLFIRI in 2L+ colorectal adenocarcinoma (CRC): Preliminary results from a phase 1 study. (Level 1, West Hall; Poster Bd #: E15) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_799;
P1
Clinical Trial Registration Number: NCT03715933. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Fruzaqla (fruquintinib) / Takeda
Phase Ib/II study of fruquintinib plus 5-fluorouracil/leucovorin after progression on fruquintinib monotherapy in metastatic colorectal cancer. (Level 1, West Hall; Poster Bd #: E14) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_798;
P1/2
Clinical Trial Registration Number: ChiCTR2000032640. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Cyramza (ramucirumab) / Eli Lilly
Phase II study of FOLFIRI with low-dose irinotecan plus ramucirumab as second-line treatment in Japanese patients with metastatic colorectal cancer (RINDO study). (Level 1, West Hall; Poster Bd #: E11) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_795;
Clinical Trial Registration Number: jRCTs041180074. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Avastin (bevacizumab) / Roche
Bevacizumab plus mFOLFOX6/FOLFIRI sequential bevacizumab plus capecitabine maintenance in RAS-mutated advanced colorectal cancer: A real-world study of first-line/second-line conversion therapy. (Level 1, West Hall; Poster Bd #: C14) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_733;
P4
Clinical Trial Registration Number: ChiCTR2100042553. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Avastin (bevacizumab) / Roche
Survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis. (Level 1, West Hall; Poster Bd #: B19) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_720;
The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Validation of PDACai v2.0 in predicting relative benefit from frontline FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GA) for patients (pts) with metastatic pancreatic cancer (mPDAC). (Level 1, West Hall; Poster Bd #: K12) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_645;
The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
A real-world prospective analysis of the relationship between nanoliposomal irinotecan and fluorouracil with folinic acid and neutropenia in patients with pancreatic cancer (NAPOLEON-2 study, NN-2401). (Level 1, West Hall; Poster Bd #: J24) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_639;
Clinical Trial Registration Number: UMIN000043939. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Effects of tumor treating fields (TTFields) with FOLFIRINOX on BRCA WT pancreatic cancer cells. (Level 1, West Hall; Poster Bd #: J15) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_610;
The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Real-world evidence of nanoliposomal irinotecan and fluorouracil with folinic acid in patients with unresectable or recurrent pancreatic cancer: Final results of a multicenter observational study. (Level 1, West Hall; Poster Bd #: H9) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_588;
Clinical Trial Registration Number: UMIN000043939. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- leucovorin calcium / Generic mfg.
Impact of UGT1A1*28 polymorphism on tolerability in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX in NAPOLI 3. (Level 1, West Hall; Poster Bd #: H5) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_584;
P3
Clinical Trial Registration Number: NCT04083235. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- leucovorin calcium / Generic mfg.
Effect of dose adjustments on overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX: A post hoc analysis of NAPOLI 3. (Level 1, West Hall; Poster Bd #: H4) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_583;
P3
Clinical Trial Registration Number: NCT04083235. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- leucovorin calcium / Generic mfg.
Cost-effectiveness of NALIRIFOX compared to other first-line treatments for metastatic pancreatic cancer. (Level 1, West Hall; Poster Bd #: H21) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_576;
The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Tecentriq (atezolizumab) / Roche, Reolysin (pelareorep) / Oncolytics, Andrus Reo
GOBLET study: Results of the safety run-in for first-line metastatic pancreatic ductal adenocarcinoma (PDAC) patients treated with pelareorep + modified FOLFIRINOX +/- atezolizumab. (Level 1, West Hall; Poster Bd #: H18) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_572;
Clinical Trial Registration Number: 2020-003996-16. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Lenvatinib plus hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leucovorin versus lenvatinib alone for advanced hepatocellular carcinoma. (Level 1, West Hall; Poster Bd #: C6) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_538;
The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Real-world use of supportive medications to prevent and manage key adverse events during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), FFX without 5FU bolus, and gemcitabine+nab-paclitaxel (GnP). (Level 1, West Hall; Poster Bd #: G9) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_487;
The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Real-world excess costs associated with hematologic adverse events (hAEs) during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), FFX without 5FU bolus, and gemcitabine+nab-paclitaxel (GnP). (Level 1, West Hall; Poster Bd #: G7) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_485;
The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Real-world dose intensity (DI) and time to adverse events (AEs) in a commercial database during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), FFX without 5FU bolus, and gemcitabine + nab-paclitaxel (GnP). (Level 1, West Hall; Poster Bd #: G6) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_484;
The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Overall survival (OS) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with first-line (1L) FOLFIRINOX (FFX): Bridging the gap between the NAPOLI 3 trial and real-world practice. (Level 1, West Hall; Poster Bd #: G4) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_482;
The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Redefining the use of a first-line FOLFIRINOX-like regimen in older patients with metastatic pancreatic cancer. (Level 1, West Hall; Poster Bd #: F19) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_418;
P2
Clinical Trial Registration Number: NCT05360732. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Opdivo (nivolumab) / BMS
SOX/FOLFOX+nivolumab followed by conversion surgery for HER2 negative primary gastric or gastroesophageal junction cancer with oligo-metastasis or borderline resectable tumors: Early results of a consecutive 41 cases. (Level 1, West Hall; Poster Bd #: H2) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_370;
The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- leucovorin calcium / Generic mfg., carboplatin / Generic mfg., paclitaxel / Generic mfg.
Phase II study of neoadjuvant NALIRIFOX followed by chemoradiation with paclitaxel and carboplatin in locally advanced gastroesophageal cancer. (Level 1, West Hall; Poster Bd #: F17) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_315;
P2
Clinical Trial Registration Number: NCT04656041. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Phase II study of neoadjuvant chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel for resectable esophageal squamous cell carcinoma. (Level 1, West Hall; Poster Bd #: E8) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_306;
Clinical Trial Registration Number: jRCTs031200094. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Cyramza (ramucirumab) / Eli Lilly
FOLFIRI-ramucirumab (FOLFIRI-Ram) versus ramucirumab-paclitaxel (Ram-Pac) in the second line (2L) for patients with advanced upper gastrointestinal (UGI) cancer: A real-world propensity-score matched analysis of survival. (Level 1, West Hall; Poster Bd #: C16) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_227;
The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Final analysis of modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for RAS wild-type and left-sided metastatic colorectal cancer: The DEEPER trial (JACCRO CC-13). (Level 2, Ballroom) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_173;
Clinical Trial Registration Number: jRCTs061180022. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- Effect of baseline geriatric and quality of life assessments on treatment outcomes in ECOG-ACRIN EA2186 (GIANT): A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-na (Level 2, Ballroom) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_162;
P2
Clinical Trial Registration Number: NCT04233866. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- | 5-fluorouracil / Generic mfg.
Retrospective data, Journal: Long-Term Outcomes of 5-Fluorouracil-Related Early-Onset Toxicities: A Retrospective Cohort Study. (Pubmed Central) - Dec 17, 2024
Early-onset toxicities related to 5-FU during the first cycle of FOLFOX/FOLFIRINOX treatment were associated with poor outcomes. Early recognition and prompt intervention are pertinent to improve outcomes in patients receiving fluoropyrimidine chemotherapy.
- | Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Journal, Metastases: Circulating Hepcidin Levels Are an Independent Predictor of Survival in Microsatellite Stable Metastatic Colorectal Cancer Patient Candidates for Standard First-Line Treatment. (Pubmed Central) - Dec 17, 2024
Our data show that baseline serum levels of hepcidin are an independent risk factor for OS in MSS mCRC patients undergoing standard first-line treatment. Further prospective and extensive studies are needed to confirm and validate our findings.
- || Review, Journal: Correlation Between Antihypertensive Drugs and Survival Among Patients with Pancreatic Ductal Adenocarcinoma. (Pubmed Central) - Dec 17, 2024
Antihypertensive medications, particularly those belonging to the pharmacological classes of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and calcium channel blockers, are commonly prescribed and have well-established safety profiles, particularly among patients with pancreatic cancer who are affected by multiple comorbidities. Therefore, we emphasize the preclinical and clinical evidence supporting the use of antihypertensive agents in the treatment of pancreatic cancer, emphasizing their beneficial chemosensitizing effects.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Journal, Tumor microenvironment, PD(L)-1 Biomarker, IO biomarker, Metastases: Identification of prognostic tumor microenvironment in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors. (Pubmed Central) - Dec 13, 2024
The differences in the initial TME of patients, especially in tumor-infiltrating T lymphocytes, may be potential biomarkers for predicting response and prognosis. This finding provides clues to search for biomarkers for this triple combination therapy in advanced HCC.
- || certepetide (LSTA1) / Lisata Therap
Trial completion date, Trial primary completion date: BOLSTER: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 13, 2024
P2, N=80, Recruiting, Sponsor: Lisata Therapeutics, Inc.
This finding provides clues to search for biomarkers for this triple combination therapy in advanced HCC. Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
- |||||||||| Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
New P3 trial: AtezoTRIBE2: FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. (clinicaltrials.gov) - Dec 13, 2024
P3, N=238, Recruiting, Sponsor: Gruppo Oncologico del Nord-Ovest
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal, Metastases: Distal Pancreatectomy with Celiac Axis and Venous Resection with Hepatic Artery and Venous Reconstruction (DP-CARV) for Locally Advanced Pancreatic Adenocarcinoma. (Pubmed Central) - Dec 12, 2024
Common hepatic artery reconstruction during DP-CAR represents a safe surgical option to reduce ischemic events related to celiac trunk resection, particularly in the FOLFIRINOX era. This technique integrated the surgical armamentarium of surgeons dealing with LAPC.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal: Primary Squamous Cell Carcinoma of the Gallbladder: Case Report. (Pubmed Central) - Dec 12, 2024
After 2?months, liver metastasis was diagnosed, and a chemotherapy regimen consisting of gemcitabine, cisplatin, and pembrolizumab was started...There is no consensus about the best adjuvant treatment. The results obtained from this patient might help elucidate the role of adjuvant therapies in treating this rare case report.
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change, Trial primary completion date, Mismatch repair: CheckMate 8HW: A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Dec 11, 2024
P3, N=1147, Recruiting, Sponsor: Bristol-Myers Squibb
The results obtained from this patient might help elucidate the role of adjuvant therapies in treating this rare case report. N=831 --> 1147 | Trial primary completion date: Jun 2025 --> Aug 2024
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Retrospective data, Journal, Real-world evidence, Real-world: FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study. (Pubmed Central) - Dec 11, 2024
The FOLFOX-HAIC combined with targeted immunotherapy regimen is effective in patients with unresectable HCC, demonstrated by a high surgical conversion rate and manageable adverse effects. This regimen represents a potential novel first-line treatment option for HCC.
- | Keytruda (pembrolizumab) / Merck (MSD), Visudyne (verteporfin) / Novartis
Enrollment open, Metastases: Photoradiation with Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Dec 11, 2024
P2, N=25, Recruiting, Sponsor: Mayo Clinic
This regimen represents a potential novel first-line treatment option for HCC. Not yet recruiting --> Recruiting
- |||||| Rybrevant (amivantamab-vmjw) / J&J
Enrollment open, Trial completion date, Metastases: OrigAMI-2: A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (clinicaltrials.gov) - Dec 10, 2024
P3, N=1000, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Jan 2032 --> Dec 2032
- | methotrexate / Generic mfg.
Journal: Effectiveness and Efficiency Comparison of One-Day vs Eight-Day Methotrexate Protocols in Managing Low-Risk Gestational Trophoblastic Neoplasia. (Pubmed Central) - Dec 9, 2024
Not yet recruiting --> Recruiting | Trial completion date: Jan 2032 --> Dec 2032 Hasan Sadikin General Hospital from January 2020 to December 2023: a 1-day Methotrexate (MTX) 300 mg/m
- | methotrexate / Generic mfg.
Journal: Therapeutic drug monitoring of methotrexate by disposable SPCE biosensor for personalized medicine. (Pubmed Central) - Dec 7, 2024
Hasan Sadikin General Hospital from January 2020 to December 2023: a 1-day Methotrexate (MTX) 300 mg/m To meet the requirements of personalized medicine for MTX-patients, we developed a disposable biosensor with wide detection range from 0.01 to 1
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Role of volumetric tumor enhancement on CT in predicting overall survival in patients with unresectable pancreatic ductal adenocarcinoma. (Pubmed Central) - Dec 7, 2024
To meet the requirements of personalized medicine for MTX-patients, we developed a disposable biosensor with wide detection range from 0.01 to 1 Percentage reduction in enhancing tumor volume was related to OS in non-surgical PDAC patients treated with FOLFIRINOX chemotherapy and could potentially be incorporated into patient survival prediction models.
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., paclitaxel / Generic mfg.
Preclinical, Journal: Design and Synthesis of Propargyloxy Functionalized Pyrazole-based Aurones: Exploring Their Potent Anticancer Properties Against AGS and MCF-7 Cell Lines. (Pubmed Central) - Dec 6, 2024
Percentage reduction in enhancing tumor volume was related to OS in non-surgical PDAC patients treated with FOLFIRINOX chemotherapy and could potentially be incorporated into patient survival prediction models. Among these tested compounds, five (10d-f, 11e, and 11f) displayed potent cytotoxic properties for AGS cancer cell line with IC50 values ranging from 19.7
- | methotrexate / Generic mfg.
Journal: Accidental methotrexate overdose leading to multisystem toxicity: A case report. (Pubmed Central) - Dec 6, 2024
This case was one of severe Methotrexate poisoning, leading to profound systemic toxicity. Thus, timely recognition, immediate drug withdrawal, and aggressive supportive care comprising Folinic Acid therapy and hydration played a major role in this patient's management.
- || Review, Journal: Primary Pulmonary Choriocarcinoma With Lymph Node Metastasis: A Case Report and Brief Review. (Pubmed Central) - Dec 6, 2024
Her post-treatment PET scan showed no evidence of disease, and her ?-hCG remains at nadir level. She is currently on monthly hCG surveillance and is in good condition.
- | Biomarker, Journal, Gene Signature, IO biomarker: Radioresistance-related gene signatures identified by transcriptomics characterize the prognosis and immune landscape of pancreatic cancer patients. (Pubmed Central) - Dec 6, 2024
We herein presented signature genes correlated with radioresistance in PC and established a risk score model competent in estimating patients' clinical outcomes and response to antitumor drugs. The above evidence could contribute to comprehending the mechanisms of radioresistance and identifying the underlying therapy targeting.
- | Tecentriq (atezolizumab) / Roche
Enrollment closed: Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer (clinicaltrials.gov) - Dec 6, 2024
P2, N=240, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
The above evidence could contribute to comprehending the mechanisms of radioresistance and identifying the underlying therapy targeting. Recruiting --> Active, not recruiting